CureVac (CVAC)
(Real Time Quote from BATS)
$3.27 USD
-0.10 (-2.97%)
Updated Aug 27, 2024 10:18 AM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
CureVac N.V. (CVAC) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$7.15 | $16.00 | $2.60 | 112.17% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for CureVac N.V. comes to $7.15. The forecasts range from a low of $2.60 to a high of $16.00. The average price target represents an increase of 112.17% from the last closing price of $3.37.
Analyst Price Targets (4 )
Broker Rating
CureVac N.V. currently has an average brokerage recommendation (ABR) of 2.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 2.50 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, two are Strong Buy, representing 33.33% of all recommendations. A month ago, Strong Buy represented 33.33%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/CVAC.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.50 | 2.50 | 2.50 | 2.50 | 2.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/15/2024 | SVB Securities | Mani Foroohar | Hold | Hold |
7/3/2024 | JMP Securities | Roy Buchanan | Strong Buy | Strong Buy |
4/5/2024 | Guggenheim Securities | Evan Wang | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.50 |
ABR (Last week) | 2.50 |
# of Recs in ABR | 6 |
Average Target Price | $7.15 |
LT Growth Rate | 26.40% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 83 of 253 |
Current Quarter EPS Est: | 0.67 |